
Ta Hsung Tung
Examiner (ID: 4022)
| Most Active Art Unit | 1102 |
| Art Unit(s) | 1744, 1104, 1753, 1106, 1102, 1743, 2899, 2701, 2901 |
| Total Applications | 1660 |
| Issued Applications | 1317 |
| Pending Applications | 54 |
| Abandoned Applications | 289 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16343632
[patent_doc_number] => 20200308282
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-01
[patent_title] => CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
[patent_app_type] => utility
[patent_app_number] => 16/827580
[patent_app_country] => US
[patent_app_date] => 2020-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39734
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16827580
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/827580 | CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING | Mar 22, 2020 | Abandoned |
Array
(
[id] => 16613664
[patent_doc_number] => 20210032317
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-04
[patent_title] => VISTA-IG FOR TREATMENT OF AUTOIMMUNE, ALLERGIC AND INFLAMMATORY DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/820116
[patent_app_country] => US
[patent_app_date] => 2020-03-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 89947
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16820116
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/820116 | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders | Mar 15, 2020 | Issued |
Array
(
[id] => 16525286
[patent_doc_number] => 20200399366
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-24
[patent_title] => METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/818820
[patent_app_country] => US
[patent_app_date] => 2020-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54829
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -40
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16818820
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/818820 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS | Mar 12, 2020 | Abandoned |
Array
(
[id] => 16283778
[patent_doc_number] => 20200277380
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-03
[patent_title] => PD-L1-SPECIFIC ANTIBODIES AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 16/818621
[patent_app_country] => US
[patent_app_date] => 2020-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10470
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16818621
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/818621 | PD-L1-specific antibodies and methods of using the same | Mar 12, 2020 | Issued |
Array
(
[id] => 16238294
[patent_doc_number] => 20200255528
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-13
[patent_title] => B7-H4 ANTIBODIES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/814627
[patent_app_country] => US
[patent_app_date] => 2020-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42768
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -47
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16814627
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/814627 | B7-H4 antibodies and methods of use thereof | Mar 9, 2020 | Issued |
Array
(
[id] => 17867392
[patent_doc_number] => 20220290128
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-15
[patent_title] => CAR LIBRARY AND scFv MANUFACTURING METHOD
[patent_app_type] => utility
[patent_app_number] => 17/428214
[patent_app_country] => US
[patent_app_date] => 2020-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 113216
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 276
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17428214
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/428214 | CAR library and scFv manufacturing method | Feb 3, 2020 | Issued |
Array
(
[id] => 16468207
[patent_doc_number] => 20200369744
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-26
[patent_title] => BSL2v2c2-Ig POLYPEPTIDES
[patent_app_type] => utility
[patent_app_number] => 16/778159
[patent_app_country] => US
[patent_app_date] => 2020-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 70101
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16778159
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/778159 | BSL2v2c2-Ig POLYPEPTIDES | Jan 30, 2020 | Abandoned |
Array
(
[id] => 18717878
[patent_doc_number] => 11795209
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-24
[patent_title] => PVRIG polypeptides and methods of treatment
[patent_app_type] => utility
[patent_app_number] => 16/775133
[patent_app_country] => US
[patent_app_date] => 2020-01-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 223
[patent_figures_cnt] => 345
[patent_no_of_words] => 58474
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 100
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16775133
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/775133 | PVRIG polypeptides and methods of treatment | Jan 27, 2020 | Issued |
Array
(
[id] => 16807915
[patent_doc_number] => 20210130468
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-06
[patent_title] => Antigen Binding Proteins that Bind PD-1
[patent_app_type] => utility
[patent_app_number] => 16/742712
[patent_app_country] => US
[patent_app_date] => 2020-01-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23922
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16742712
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/742712 | Antigen binding proteins that bind PD-1 | Jan 13, 2020 | Issued |
Array
(
[id] => 15866303
[patent_doc_number] => 20200140555
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-07
[patent_title] => Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS
[patent_app_type] => utility
[patent_app_number] => 16/728642
[patent_app_country] => US
[patent_app_date] => 2019-12-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34046
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 177
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16728642
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/728642 | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the CNS | Dec 26, 2019 | Issued |
Array
(
[id] => 18341911
[patent_doc_number] => 11639385
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-05-02
[patent_title] => Anti-PD-1 antibodies
[patent_app_type] => utility
[patent_app_number] => 16/728653
[patent_app_country] => US
[patent_app_date] => 2019-12-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 37
[patent_no_of_words] => 18519
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16728653
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/728653 | Anti-PD-1 antibodies | Dec 26, 2019 | Issued |
Array
(
[id] => 18355074
[patent_doc_number] => 11643464
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-05-09
[patent_title] => Reducing systemic regulatory T cell levels or activity for treatment of a retinal degeneration disorder
[patent_app_type] => utility
[patent_app_number] => 16/728587
[patent_app_country] => US
[patent_app_date] => 2019-12-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 76
[patent_no_of_words] => 28533
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16728587
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/728587 | Reducing systemic regulatory T cell levels or activity for treatment of a retinal degeneration disorder | Dec 26, 2019 | Issued |
Array
(
[id] => 19931740
[patent_doc_number] => 12304937
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-20
[patent_title] => Leptin immunogens, hybridoma cells, monoclonal antibodies, polyclonal antibodies and use thereof
[patent_app_type] => utility
[patent_app_number] => 17/424484
[patent_app_country] => US
[patent_app_date] => 2019-12-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 808
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17424484
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/424484 | Leptin immunogens, hybridoma cells, monoclonal antibodies, polyclonal antibodies and use thereof | Dec 23, 2019 | Issued |
Array
(
[id] => 18518531
[patent_doc_number] => 11708412
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-07-25
[patent_title] => Methods for treating hematologic cancers
[patent_app_type] => utility
[patent_app_number] => 16/724759
[patent_app_country] => US
[patent_app_date] => 2019-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 23
[patent_no_of_words] => 40119
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16724759
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/724759 | Methods for treating hematologic cancers | Dec 22, 2019 | Issued |
Array
(
[id] => 16900797
[patent_doc_number] => 20210179713
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-17
[patent_title] => ANTI-PD-1 ANTIBODIES, ACTIVATABLE ANTI-PD-1 ANTIBODIES, AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/725587
[patent_app_country] => US
[patent_app_date] => 2019-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 118076
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16725587
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/725587 | ANTI-PD-1 ANTIBODIES, ACTIVATABLE ANTI-PD-1 ANTIBODIES, AND METHODS OF USE THEREOF | Dec 22, 2019 | Abandoned |
Array
(
[id] => 16206552
[patent_doc_number] => 20200239542
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-30
[patent_title] => B7-H5, A Costimulatory Polypeptide
[patent_app_type] => utility
[patent_app_number] => 16/707719
[patent_app_country] => US
[patent_app_date] => 2019-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10850
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16707719
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/707719 | B7-H5, a costimulatory polypeptide | Dec 8, 2019 | Issued |
Array
(
[id] => 15678403
[patent_doc_number] => 20200093865
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-26
[patent_title] => GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/701818
[patent_app_country] => US
[patent_app_date] => 2019-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 69312
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16701818
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/701818 | Genetically engineered hematopoietic stem cells and uses thereof | Dec 2, 2019 | Issued |
Array
(
[id] => 18020607
[patent_doc_number] => 20220372106
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => CD86 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/298506
[patent_app_country] => US
[patent_app_date] => 2019-11-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 79249
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -171
[patent_words_short_claim] => 123
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17298506
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/298506 | CD86 variant immunomodulatory proteins and uses thereof | Nov 26, 2019 | Issued |
Array
(
[id] => 16156605
[patent_doc_number] => 20200216535
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-09
[patent_title] => ANTI-PD1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS
[patent_app_type] => utility
[patent_app_number] => 16/684237
[patent_app_country] => US
[patent_app_date] => 2019-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16072
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16684237
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/684237 | Anti-PD1 antibodies and their use as therapeutics and diagnostics | Nov 13, 2019 | Issued |
Array
(
[id] => 17312838
[patent_doc_number] => 20210401886
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => METHODS AND MATERIALS FOR TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 17/288212
[patent_app_country] => US
[patent_app_date] => 2019-10-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7611
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17288212
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/288212 | Methods and materials for treating cancer | Oct 30, 2019 | Issued |